THERAPY DOSSIER · th-730050bb85a6

Helix B surface peptide (HBSP), an 11 amino acid peptide (QEQLERALNSS) derived from erythropoietin

Biologic · Peptide (Helix B surface peptide, HBSP, EPO-derived); no confident ChEMBL match, preclinical

Evidence & regulatory context

Mechanism: Peptide (Helix B surface peptide, HBSP, EPO-derived); no confident ChEMBL match, preclinical
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24282430 ↗2013Reported benefit

Protective effects of HBSP on ischemia reperfusion and cyclosporine a induced renal injury.

RatIschaemia-reperfusionRenalSprague-Dawleymalen = n = 6 per group across 4 groups (IR, IR + CsA, IR + HBSP, I…intraperitoneal8 nmol/kgCommenced after reperfusion

Model: Right renal pedicle occlusion for 45 min with left nephrectomy before reperfusion, followed by 2 weeks of reperfusion, with or without daily cyclosporine A 25 mg/kg by gavage

HBSP reduced blood urea nitrogen in the IR + CsA group at 1 and 2 weeks (8.0 +/- 0.9 and 9.4 +/- 1.7 versus 14.4 +/- 1.4 and 14.7 +/- 0.9 mmol/L) and lowered the urinary protein/creatinine ratio at 2 weeks. It reduced the tubulointerstitial damage score (3.5 +/- 0.3 versus 5.5 +/- 0.5), collagen de…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…